MA53446A - Collections de peptides, d'agents peptidiques et procédés d'utilisation de ceux-ci - Google Patents

Collections de peptides, d'agents peptidiques et procédés d'utilisation de ceux-ci

Info

Publication number
MA53446A
MA53446A MA053446A MA53446A MA53446A MA 53446 A MA53446 A MA 53446A MA 053446 A MA053446 A MA 053446A MA 53446 A MA53446 A MA 53446A MA 53446 A MA53446 A MA 53446A
Authority
MA
Morocco
Prior art keywords
collections
peptides
methods
peptide agents
peptide
Prior art date
Application number
MA053446A
Other languages
English (en)
French (fr)
Inventor
John Hanney Mcgee
Mark Joseph Mulvihill
Araghi Raheleh Rezaei
Ty Matthew Thomson
Gregory L Verdine
Sebastian Christof Theodor Wahl
Yue-Mei Zhang
Original Assignee
Fog Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fog Pharmaceuticals Inc filed Critical Fog Pharmaceuticals Inc
Publication of MA53446A publication Critical patent/MA53446A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869Methods for sequencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1037Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Biomedical Technology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
MA053446A 2018-08-20 2019-08-20 Collections de peptides, d'agents peptidiques et procédés d'utilisation de ceux-ci MA53446A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862719996P 2018-08-20 2018-08-20

Publications (1)

Publication Number Publication Date
MA53446A true MA53446A (fr) 2021-06-30

Family

ID=69591277

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053446A MA53446A (fr) 2018-08-20 2019-08-20 Collections de peptides, d'agents peptidiques et procédés d'utilisation de ceux-ci

Country Status (14)

Country Link
US (1) US12398178B2 (https=)
EP (1) EP3840766A4 (https=)
JP (1) JP2021535108A (https=)
KR (1) KR20210060482A (https=)
CN (1) CN113039195A (https=)
AU (1) AU2019326423A1 (https=)
BR (1) BR112021003113A2 (https=)
CA (1) CA3110082A1 (https=)
EA (1) EA202190531A1 (https=)
IL (1) IL280931A (https=)
MA (1) MA53446A (https=)
MX (1) MX2021001943A (https=)
SG (1) SG11202101672YA (https=)
WO (1) WO2020041270A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018329956A1 (en) 2017-09-07 2020-08-20 Fog Pharmaceuticals, Inc. Agents modulating beta-catenin functions and methods thereof
MX2021001943A (es) 2018-08-20 2021-07-15 Fog Pharmaceuticals Inc Colecciones de péptidos, agentes peptídicos y métodos de uso de los mismos.
GB201909103D0 (en) * 2019-06-25 2019-08-07 Univ Bath Compounds
KR20240031957A (ko) * 2021-06-08 2024-03-08 포그 파마슈티컬스 인코포레이티드 스테이플화된 펩티드 및 이의 방법

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2586387T3 (es) 2003-11-05 2016-10-14 Dana-Farber Cancer Institute, Inc. Péptidos alfa helicoidales adecuados para activar o inhibir la muerte celular
EP2997973A1 (en) 2006-11-15 2016-03-23 Dana-Farber Cancer Institute, Inc. Stabalized maml peptides and uses thereof
BRPI0720306A2 (pt) 2006-12-14 2014-02-04 Aileron Therapeutics Inc Sistemas de macrociclização da bis-sufidrila
DK2118123T3 (en) 2007-01-31 2016-01-25 Dana Farber Cancer Inst Inc Stabilized p53 peptides and uses thereof
US8592377B2 (en) 2007-03-28 2013-11-26 President And Fellows Of Harvard College Stitched polypeptides
CA2685568A1 (en) 2007-05-02 2008-11-13 Dana-Farber Cancer Institute, Inc. Methods of treating diabetes using bad bh3 domain peptide
CA2700925C (en) 2007-09-26 2016-08-23 Dana Farber Cancer Institute Methods and compositions for modulating bcl-2 family polypeptides
EP2247606B1 (en) 2008-01-23 2019-08-21 Dana-Farber Cancer Institute, Inc. Compositions and methods for the treatment of viral infections
EP2356139A4 (en) 2008-07-23 2013-01-09 Harvard College LIGURE COMBINED POLYPEPTIDES
EP3401684B1 (en) 2008-10-10 2022-03-16 Dana Farber Cancer Institute, Inc. Chemical modulators of pro-apoptotic bax and bcl-2 polypeptides
EP3549951A3 (en) 2008-12-09 2019-11-20 Dana Farber Cancer Institute, Inc. Methods and compositions for specific modulation of mcl-1
AU2010263056B2 (en) 2009-06-18 2016-01-07 Dana Farber Cancer Institute, Inc. Structured viral peptide compositions and methods of use
AU2010273220B2 (en) 2009-07-13 2015-10-15 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
CA2787784A1 (en) 2010-01-29 2011-08-04 Dana-Farber Cancer Institute, Inc. Small molecules for the modulation of mcl-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders
EP2590997B1 (en) 2010-07-09 2018-04-04 Dana-Farber Cancer Institute, Inc. Stabilized insulinotropic peptides and methods of use
WO2012040459A2 (en) 2010-09-22 2012-03-29 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
CA2817568A1 (en) 2010-11-12 2012-05-18 The Salk Institute For Biological Studies Intellectual Property And Tech Nology Transfer Cancer therapies and diagnostics
AU2012242502B2 (en) 2011-04-15 2016-07-28 Dana-Farber Cancer Institute, Inc. Targeting deregulated WNT signaling in cancer using stabilized alpha-helices of BCL-9
US9487562B2 (en) 2011-06-17 2016-11-08 President And Fellows Of Harvard College Stabilized polypeptides as regulators of RAB GTPase function
WO2012174409A1 (en) 2011-06-17 2012-12-20 President And Fellows Of Harvard College Stabilized variant maml peptides and uses thereof
CA2851788C (en) 2011-10-11 2022-11-29 Dana-Farber Cancer Institute, Inc. Pyrazol-3-ones that activate pro-apoptotic bax
CA2862391C (en) 2011-12-29 2023-10-10 Loren D. Walensky Stabilized antiviral fusion helices
WO2013142281A1 (en) 2012-03-20 2013-09-26 Dana Farber Cancer Institute, Inc. Inhibition of mcl-1 and/or bfl-1/a1
WO2014052647A2 (en) 2012-09-26 2014-04-03 President And Fellows Of Harvard College Proline-locked stapled peptides and uses thereof
US20150225471A1 (en) 2012-10-01 2015-08-13 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
EP3391898A3 (en) 2013-03-13 2019-02-13 President and Fellows of Harvard College Stapled and stitched polypeptides and uses thereof
AU2014227824B2 (en) 2013-03-15 2018-09-27 Dana-Farber Cancer Institute, Inc. Stabilized SOS1 peptides
EP2970417B1 (en) 2013-03-15 2019-06-19 Dana-Farber Cancer Institute, Inc. Bh4 stabilized peptides and uses thereof
EP2970418A4 (en) 2013-03-15 2016-08-17 Dana Farber Cancer Inst Inc STABILIZED EZH2 PEPTIDES
WO2014197821A1 (en) 2013-06-06 2014-12-11 President And Fellows Of Harvard College Homeodomain fusion proteins and uses thereof
JP2016523241A (ja) 2013-06-14 2016-08-08 プレジデント アンド フェローズ オブ ハーバード カレッジ 安定化されたポリペプチドインスリン受容体調節剤
US20160244494A1 (en) 2013-10-01 2016-08-25 President And Fellows Of Harvard College Stabilized polypeptides and uses thereof
KR102455171B1 (ko) 2013-12-18 2022-10-14 더 스크립스 리서치 인스티튜트 변형된 치료제, 스테이플드 펩티드 지질 접합체, 및 이의 조성물
CA2949535C (en) 2014-05-21 2023-09-12 President And Fellows Of Harvard College Ras inhibitory peptides and uses thereof
CA2979999A1 (en) 2015-03-18 2016-09-22 Massachusetts Institute Of Technology Selective mcl-1 binding peptides
US11155577B2 (en) 2015-06-22 2021-10-26 University Of Utah Research Foundation Thiol-ene based peptide stapling and uses thereof
EP3317294B1 (en) 2015-07-02 2023-03-15 Dana-Farber Cancer Institute, Inc. Stabilized anti-microbial peptides
CA2995479A1 (en) 2015-08-28 2017-03-09 Dana-Farber Cancer Institute, Inc. Peptides binding to bfl-1
US20190002506A1 (en) 2015-08-28 2019-01-03 Dana-Farber Cancer Institute, Inc. Stabilized peptides for covalent binding to target protein
WO2018071076A2 (en) 2016-07-07 2018-04-19 Northwestern University Enhanced conductivity, adhesion and environmental stability of printed graphene inks with nitrocellulose
US11034720B2 (en) * 2016-07-17 2021-06-15 University Of Utah Research Foundation Thiol-yne based peptide stapling and uses thereof
AU2018329956A1 (en) 2017-09-07 2020-08-20 Fog Pharmaceuticals, Inc. Agents modulating beta-catenin functions and methods thereof
MX2021001943A (es) 2018-08-20 2021-07-15 Fog Pharmaceuticals Inc Colecciones de péptidos, agentes peptídicos y métodos de uso de los mismos.
WO2021119537A1 (en) 2019-12-11 2021-06-17 Fog Pharmaceuticals, Inc. Technologies useful for assessing permeability
EP4121082A4 (en) 2020-03-17 2024-05-01 Fog Pharmaceuticals, Inc. Helical stapled peptides and uses thereof
AU2021314310A1 (en) 2020-07-22 2023-03-16 Fog Pharmaceuticals, Inc. Stapled peptides and methods thereof
WO2022020651A1 (en) 2020-07-22 2022-01-27 Fog Pharmaceuticals, Inc. Amino acids
KR20240031957A (ko) 2021-06-08 2024-03-08 포그 파마슈티컬스 인코포레이티드 스테이플화된 펩티드 및 이의 방법
US20240376151A1 (en) 2022-10-31 2024-11-14 Fog Pharmaceuticals, Inc. Stapled peptides and methods thereof
CN120529912A (zh) 2022-12-15 2025-08-22 帕拉比利斯药物公司 订书钉化肽及其方法
WO2024130217A1 (en) 2022-12-15 2024-06-20 Fog Pharmaceuticals, Inc. Stapled peptides and methods thereof

Also Published As

Publication number Publication date
SG11202101672YA (en) 2021-03-30
EP3840766A1 (en) 2021-06-30
US12398178B2 (en) 2025-08-26
EP3840766A4 (en) 2022-06-22
WO2020041270A1 (en) 2020-02-27
AU2019326423A1 (en) 2021-04-08
EA202190531A1 (ru) 2021-08-09
IL280931A (en) 2021-04-29
JP2021535108A (ja) 2021-12-16
US20210179665A1 (en) 2021-06-17
BR112021003113A2 (pt) 2021-05-11
MX2021001943A (es) 2021-07-15
CA3110082A1 (en) 2020-02-27
KR20210060482A (ko) 2021-05-26
CN113039195A (zh) 2021-06-25
WO2020041270A9 (en) 2020-05-07

Similar Documents

Publication Publication Date Title
EP3802617A4 (en) MULTISPECIFIC BINDING PROTEINS AND METHODS OF USE THEREOF
EP3935155A4 (en) Crispr-cas effector polypeptides and methods of use thereof
EP3634430A4 (en) MULTIBIOTICS AND METHOD OF USING THEREFORE
EP3701066A4 (en) PROTEINIDENTIFICATION PROCEDURES AND SYSTEMS
EP3765023A4 (en) SYNTHETIC DNA VECTORS AND METHODS OF USE
MA50948A (fr) Anticorps et procédés d'utilisation de ceux-ci
EP3752166A4 (en) TRIALKYN CONNECTORS AND METHOD OF USE
MA50956A (fr) Anticorps anti-cd137 et procédés d'utilisation correspondants
MA53446A (fr) Collections de peptides, d'agents peptidiques et procédés d'utilisation de ceux-ci
MA53015A (fr) Anticorps anti-sirp-bêta1 et procédés d'utilisation associés
EP3487887A4 (en) MULTI-SPECIFIC ANTI-BINDING PROTEINS AND METHOD FOR USE THEREOF
EP3980067A4 (en) ANTIBODY INTERLEUKIN FUSION PROTEIN AND METHODS OF USE
EP3383913A4 (en) ANTIBODY AGAINST FC RECEPTOR LIKE 5 AND METHOD OF USE
EP3849581A4 (en) DRY POWDER FORMULATION OF CAVEOLIN-1 PEPTIDES AND METHODS OF USE THEREOF
EP3455263A4 (en) CD40L-FC FUSION POLYPEPTIDE AND METHOD FOR USE THEREOF
EP3423438A4 (en) PLANT VIRUS MOTOR PROTEINS AND METHOD FOR USE THEREOF
EP3830128A4 (en) ANTI-MICA/B ANTIBODIES THAT BLOCK MICA/B-SHEDDING AND METHODS OF USE
EP3394098A4 (en) ANTI-MYOSTATIN ANTIBODIES AND METHOD OF USE
EP3710589A4 (en) ANTI-C1S ANTIBODIES AND METHOD OF USING
EP3911355A4 (en) RECOMBINANT LUBRICINS AND COMPOSITIONS AND METHODS OF USE THEREOF
EP3880812A4 (en) ENCAPSULATED POLYNUCLEOTIDES AND METHODS OF USE
EP4054607A4 (en) SELECTIVE HDAC6 DEGRADERS AND METHODS OF USE THEREOF
EP3768298A4 (en) HUMAN PD-L2 ANTIBODIES AND METHOD OF USING THEM
MA46844A (fr) Protéines de liaison à un antigène anti-gitr et leurs procédés d'utilisation
EP3802569A4 (en) CELL-PERMEABLE PEPTIDES AND METHODS OF USE THEREOF